Pain Management News

Implementation of tissue bridges measured within the first weeks after spinal cord injury are linked with short-and-long-term clinical improvement, according to research from The Lancet Neurology.

Avidity Biosciences Inc. has announced positive data from the phase 1/2 FORTITUDE clinical trial of a proprietary monoclonal antibody that binds to the transferrin receptor 1 conjugated with a siRNA targeting DUX4 mRNA.

DENVER — The use of several common antibiotics led to exacerbation of myasthenia gravis in a small cohort of patients, Sanem P. Uysal, MD, said in this Healio video from the American Academy of Neurology annual meeting.

Wave Life Sciences has announced positive results from its phase 1b/2a clinical trial of WVE-003, a potential disease-modifying therapeutic for Huntington’s disease.

SAN DIEGO — Those with migraine who switched from an oral triptan to ubrogepant reported superior outcomes compared with patients who chose another triptan,, according to data presented at the American Headache Society Annual Scientific Meeting.

SAN DIEGO — Patients who used two or more triptans for migraine faced more acute treatment, more emergency-related hospital visits and higher medical costs compared with those who used one, data show.

Healio has launched a new special report on medical cannabis that summarizes the current scientific research and incorporates expert opinion.

The European Commission has authorized a subcutaneous injection of Ocrevus to treat relapsing multiple sclerosis as well as primary progressive MS, according to the manufacturer.

SAN DIEGO — In a small cohort of adults with headache, the most common prodromal symptoms were light and sound sensitivity, fatigue and neck pain, according to research presented at the American Headache Society Annual Scientific Meeting.

The FDA has announced approval of a label expansion for Elevidys to include patients with Duchenne muscular dystrophy aged 4 years and older with a confirmed mutation in the DMD gene.